184 related articles for article (PubMed ID: 37526847)
21. The ideal way to design clinical trials and establishment of evidence for human cellular and tissue-based products in Japan.
Sawa Y
J Tissue Eng Regen Med; 2019 Jun; 13(6):905-907. PubMed ID: 30938062
[TBL] [Abstract][Full Text] [Related]
22. Regulatory Environment and Approvals in Cell and Gene Therapy Products Between Japan, the USA, and the EU.
Sato Y; Ono S
Ther Innov Regul Sci; 2023 Mar; 57(2):227-237. PubMed ID: 36112305
[TBL] [Abstract][Full Text] [Related]
23. New Governmental Regulatory System for Stem Cell-Based Therapies in Japan.
Hara A; Sato D; Sahara Y
Ther Innov Regul Sci; 2014 Nov; 48(6):681-688. PubMed ID: 30227468
[TBL] [Abstract][Full Text] [Related]
24. Does the Act on the Safety of Regenerative Medicine in Japan ensure "safety"?: Implications of low adverse event reporting.
Ikka T; Hatta T; Saito Y; Fujita M
Stem Cell Reports; 2023 Dec; 18(12):2297-2299. PubMed ID: 37977143
[TBL] [Abstract][Full Text] [Related]
25. Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
Lysaght T; Sugii S
Cell Stem Cell; 2016 Apr; 18(4):438-9. PubMed ID: 27058936
[No Abstract] [Full Text] [Related]
26. Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy Products.
Hayakawa T; Harris I; Joung J; Kanai N; Kawamata S; Kellathur S; Koga J; Lin YC; Maruyama Y; McBlane J; Nishimura T; Renner M; Ridgway A; Salmikangas P; Sakamoto N; Sato D; Sato Y; Toda Y; Umezawa A; Werner M; Wicks S
Biologicals; 2016 Sep; 44(5):467-79. PubMed ID: 27461129
[TBL] [Abstract][Full Text] [Related]
27. Conditional approval: Japan lowers the bar for regenerative medicine products.
Sipp D
Cell Stem Cell; 2015 Apr; 16(4):353-6. PubMed ID: 25842975
[TBL] [Abstract][Full Text] [Related]
28. Survey of genetic counselors identifies a knowledge gap discerning properly regulated cell and gene therapy trials.
Geiselman LA; Wetherill L; Graham BH; Payne K; Hopewell EL
Cytotherapy; 2024 Jan; 26(1):88-95. PubMed ID: 37747395
[TBL] [Abstract][Full Text] [Related]
29. Accelerating Cell Therapy for Stroke in Japan: Regulatory Framework and Guidelines on Development of Cell-Based Products.
Houkin K; Shichinohe H; Abe K; Arato T; Dezawa M; Honmou O; Horie N; Katayama Y; Kudo K; Kuroda S; Matsuyama T; Miyai I; Nagata I; Niizuma K; Sakushima K; Sasaki M; Sato N; Sawanobori K; Suda S; Taguchi A; Tominaga T; Yamamoto H; Yamashita T; Yoshimine T;
Stroke; 2018 Apr; 49(4):e145-e152. PubMed ID: 29581346
[No Abstract] [Full Text] [Related]
30. Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan.
Carolina IL; Antònia A; Mercè O; Antonio V
Expert Opin Biol Ther; 2022 Jul; 22(7):831-842. PubMed ID: 35762253
[TBL] [Abstract][Full Text] [Related]
31. [Industrialization of regenerative medicine in Japan].
Sugawara K; Hata K
Clin Calcium; 2008 Dec; 18(12):1751-6. PubMed ID: 19043189
[TBL] [Abstract][Full Text] [Related]
32. Stem cell research and therapies in Argentina: the legal and regulatory approach.
de Arzuaga FC
Stem Cells Dev; 2013 Dec; 22 Suppl 1():40-3. PubMed ID: 24304074
[TBL] [Abstract][Full Text] [Related]
33. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
Nagai S
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
[TBL] [Abstract][Full Text] [Related]
34. Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon.
Chisholm J; Ruff C; Viswanathan S
Cytotherapy; 2019 Jul; 21(7):686-698. PubMed ID: 31196821
[TBL] [Abstract][Full Text] [Related]
35. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
[TBL] [Abstract][Full Text] [Related]
36. Japanese Laws and the Current Status of Regenerative Medicine in the Tohoku Region.
Kamano Y; Terajima N; Chiba Y; Suresh VV; Saito M
J Contemp Dent Pract; 2023 Feb; 24(2):120-128. PubMed ID: 37272144
[TBL] [Abstract][Full Text] [Related]
37. Overview of the clinical application of regenerative medicine products in Japan.
Tsubouchi M; Matsui S; Banno Y; Kurokawa K; Kawakami K
Health Policy; 2008 Oct; 88(1):62-72. PubMed ID: 18395290
[TBL] [Abstract][Full Text] [Related]
38. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea.
Choi M; Han E; Lee S; Kim T; Shin W
Adv Exp Med Biol; 2015; 871():163-79. PubMed ID: 26374218
[TBL] [Abstract][Full Text] [Related]
39. New Japanese initiatives on stem cell therapies.
Konomi K; Tobita M; Kimura K; Sato D
Cell Stem Cell; 2015 Apr; 16(4):350-2. PubMed ID: 25842974
[TBL] [Abstract][Full Text] [Related]
40. Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent stem cells and cell sheet technology: A report of the Symposium of Regenerative Medicine for Patients.
Okano T; Sawa Y; Barber E; Umezawa A
Regen Ther; 2015 Dec; 2():2-5. PubMed ID: 31245453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
